{"id":"placebo-b-after-cp","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a placebo, this agent contains no active pharmaceutical ingredient and produces no direct molecular or biological effect. It is used as a control comparator in clinical trials to assess the efficacy and safety of active investigational drugs by isolating the true drug effect from placebo response.","oneSentence":"Placebo B is an inert control substance with no active pharmacological mechanism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:38.566Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT02443077","phase":"PHASE3","title":"Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-10-12","conditions":"Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type","enrollment":94},{"nctId":"NCT07349771","phase":"PHASE2","title":"Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-01-31","conditions":"Hematopoietic and Lymphatic System Neoplasm","enrollment":72},{"nctId":"NCT04877756","phase":"PHASE2","title":"Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery","status":"COMPLETED","sponsor":"Olix Pharmaceuticals, Inc.","startDate":"2021-08-19","conditions":"Hypertrophic Scar","enrollment":22},{"nctId":"NCT01493843","phase":"PHASE2","title":"Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2012-01-20","conditions":"Non-Small Cell Lung Cancer","enrollment":501},{"nctId":"NCT00723528","phase":"PHASE3","title":"An Efficacy and Safety Study of Ustekinumab (CNTO 1275) in Participants With Plaque Psoriasis","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2008-03","conditions":"Psoriasis","enrollment":158}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo B (After CP)","genericName":"Placebo B (After CP)","companyName":"Janssen Pharmaceutical K.K.","companyId":"janssen-pharmaceutical-k-k","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}